Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy

Paolo Manca1, Davide Stolfo1,2, Marco Merlo1

  • 1Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy.

Insights

In non-ischaemic dilated cardiomyopathy, over half of patients achieved improved ejection fraction (impEF). However, a significant portion experienced a recurrent decline, increasing their risk of adverse outcomes like death or heart transplantation.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Cardiomyopathy Studies

Background:

  • The definition of heart failure with improved ejection fraction (HFimpEF) highlights the need for longitudinal left ventricular ejection fraction (LVEF) assessment.
  • Long-term progression and outcomes in the HFimpEF subgroup, particularly in non-ischaemic dilated cardiomyopathy (NICM), remain underexplored.

Purpose of the Study:

  • To investigate LVEF trajectories in patients with NICM and improved ejection fraction (impEF).
  • To correlate these LVEF trajectories with clinical outcomes, including death, heart transplantation, and left ventricular assist device implantation.

Main Methods:

  • Analysis of consecutive NICM patients from the Trieste Heart Muscle Disease Registry with baseline LVEF ≤40% and at least one follow-up LVEF assessment.
  • ImpEF defined as baseline LVEF ≤40% with a subsequent increase of ≥10% and LVEF >40%. Transient impEF identified by recurrent LVEF ≤40% during follow-up.
  • Primary endpoint: composite of all-cause death, heart transplantation, and left ventricular assist device (D/HT/LVAD).

Main Results:

  • 57% of 800 NICM patients (460 individuals) achieved impEF, with a median time to improvement of 13 months.
  • Transient impEF was observed in 41% of the impEF group (189 patients) and was linked to a 2.54-fold increased risk of D/HT/LVAD compared to persistent impEF.
  • The association between declining LVEF and D/HT/LVAD risk was non-linear, showing a sharp increase with up to an 8% point reduction in LVEF.

Conclusions:

  • A high rate of impEF (57%) was observed in NICM patients.
  • Recurrent LVEF decline occurred in approximately 40% of impEF patients, significantly associated with an increased risk of D/HT/LVAD.
  • Longitudinal LVEF monitoring is crucial for risk stratification in NICM patients with impEF.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
41
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
48
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
78